Skip to main content
SpringerLink
Log in

Development of Oncolytic Replication-Competent Herpes Simplex Virus Vectors

The G207 Paradigm

  • Chapter
Cancer Gene Therapy

Part of the book series: Contemporary Cancer Research ((CCR))

Abstract

Oncolytic virus therapy is a promising new strategy for treating cancer that involves replication-competent virus vectors that can replicate in situ in tumor cells, exhibit oncolytic activity by direct cytocidal effects, and then spread throughout the tumor. In addition, replication-competent virus vectors are capable of transferring and expressing foreign genes in host cells. These virus vectors are either genetically engineered (e.g., herpes simplex virus type 1 [HSV-1], adenovirus, vaccinia virus), naturally attenuated (e.g., Newcastle disease virus), or nonpathogenic in humans (e.g., reovirus), so they replicate selectively in tumor cells, but do not harm normal tissues (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kirn, D., Martuza, R. L., and Zwiebel, J. (2001) Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7, 781–787.

    Article  PubMed  CAS  Google Scholar 

  2. Martuza, R. L. (2000) Conditionally replicating herpes vectors for cancer therapy. J. Clin. Invest. 105, 841–846.

    PubMed  CAS  Google Scholar 

  3. Roizman, B. and Sears, A. E. (1996) Herpes simplex viruses and their replication. In Fields Virology, 3rd ed. (Fields, B. N., Knipe, D. M., and Howley, P. M., eds.), Lippincott-Raven, Philadelphia, pp. 2231–2296.

    Google Scholar 

  4. Roizman, B. (1996) The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc. Natl. Acad. Sci. USA 93, 11,307–11,312.

    Article  PubMed  CAS  Google Scholar 

  5. Balfour, H. H. Jr. (1999) Antiviral drugs. N. Engl. J. Med. 340, 1255–1268.

    Article  PubMed  CAS  Google Scholar 

  6. Wagner, E. K. and Bloom, D. C. (1997) Experimental investigation of herpes simplex virus latency. Clin. Microbiol. Rev. 10, 419–443.

    PubMed  CAS  Google Scholar 

  7. Nishiyama, Y. (1996) Herpesvirus genes: molecular basis of viral replication and pathogenicity. Nagoya J. Med. Sci. 59, 107–119.

    PubMed  CAS  Google Scholar 

  8. Varghese, S. and Rabkin, S. D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9, 967–978.

    Article  PubMed  CAS  Google Scholar 

  9. Rabkin, S. D. and Hernaiz Driever, P. (2001) Replication-competent herpes simplex virus vectors for cancer therapy. In Replication-Competent Viruses for Cancer Therapy (Rabkin, S. D. and Hernaiz Driever, P., eds.), Karger, Basel, Switzerland, pp. 1–45.

    Chapter  Google Scholar 

  10. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938–943.

    Article  PubMed  CAS  Google Scholar 

  11. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990) Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250, 1262–1266.

    Article  PubMed  CAS  Google Scholar 

  12. He, B., Gross, M., and Roizman, B. (1997) The gamma (1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 94, 843–848.

    Article  PubMed  CAS  Google Scholar 

  13. Farassati, F., Yang, A. D., and Lee, P. W. (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745–750.

    Article  PubMed  CAS  Google Scholar 

  14. Leib, D. A., Machalek, M. A., Williams, B. R., Silverman, R. H., and Virgin, H. W. (2000) Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Natl. Acad. Sci. USA 97, 6097–6101.

    Article  PubMed  CAS  Google Scholar 

  15. MacLean, A. R., ul-Fareed, M., Robertson, L., Harland, J., and Brown, S. M. (1991) Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the “a” sequence. J. Gen. Virol. 72, 631–639.

    PubMed  CAS  Google Scholar 

  16. Goldstein, D. J. and Weller, S. K. (1988) Factor (s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166, 41–51.

    Article  PubMed  CAS  Google Scholar 

  17. Pyles, R. B., Warnick, R. E., Chalk, C. L., Szanti, B. E., and Parysek, L. M. (1997) A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8, 533–544.

    PubMed  CAS  Google Scholar 

  18. Todo, T., Ebright, M. I., Fong, Y., and Rabkin, S. D. (2001) Oncolytic herpes simplex virus (G207) therapy for cancer: from basic to clinical. In Tumor Suppressing Viruses, Genes, and Drugs—Innovative Cancer Therapy Approaches (Maruta, H., ed.), Academic Press, San Diego, CA, pp. 45–75.

    Google Scholar 

  19. Yazaki, T., Manz, H. J., Rabkin, S. D., and Martuza, R. L. (1995) Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55, 4752–4756.

    PubMed  CAS  Google Scholar 

  20. Walker, J. R., McGeagh, K. G., Sundaresan, P., Jorgensen, T. J., Rabkin, S. D., and Martuza, R. L. (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10, 2237–2243.

    Article  PubMed  CAS  Google Scholar 

  21. Oyama, M., Ohigashi, T., Hoshi, M., et al. (2000) Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum. Gene Ther. 11, 1683–1693.

    Article  PubMed  CAS  Google Scholar 

  22. Fu, X. and Zhang, X. (2002) Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 62, 2306–2312.

    PubMed  CAS  Google Scholar 

  23. Kooby, D. A., Carew, J. F., Halterman, M. W., et al. (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207) FASEB J. 13, 1325–1334.

    PubMed  CAS  Google Scholar 

  24. Carew, J. F., Kooby, D. A., Halterman, M. W., Federoff, H. J., and Fong, Y. (1999) Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum. Gene Ther. 10, 1599–1606.

    Article  PubMed  CAS  Google Scholar 

  25. Bennett, J. J., Kooby, D. A., Delman, K., et al. (2000) Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J. Mol. Med. 78, 166–174.

    Article  PubMed  CAS  Google Scholar 

  26. Coukos, G., Makrigiannakis, A., Montas, S., et al. (2000) Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther. 7, 275–283.

    Article  PubMed  CAS  Google Scholar 

  27. Whitley, R. J. and Gnann, J. W. (2002) Viral encephalitis: familiar infections and emerging pathogens. Lancet 359 507–513.

    Article  PubMed  Google Scholar 

  28. Rampling, R., Cruickshank, G., Papanastassiou, V., et al. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859–866.

    Article  PubMed  CAS  Google Scholar 

  29. Sundaresan, P., Hunter, W. D., Martuza, R. L., and Rabkin, S. D. (2000) Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J. Virol. 74, 3832–3841.

    Article  PubMed  CAS  Google Scholar 

  30. Lopez, C. (1975) Genetics of natural resistance to herpesvirus infections in mice. Nature 258, 152–155.

    Article  PubMed  CAS  Google Scholar 

  31. Todo, T., Martuza, R. L., Rabkin, S. D., and Johnson, P. A. (2001) Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA 98, 6396–6401.

    Article  PubMed  CAS  Google Scholar 

  32. Katzin, D. S., Connor, J. D., Wilson, L. A., and Sexton, R. S. (1967) Experimental herpes simplex infection in the owl monkey. Proc. Soc. Exp. Biol. Med. 125, 391–398.

    PubMed  CAS  Google Scholar 

  33. Meignier, B., Martin, B., Whitley, R. J., and Roizman, B. (1990) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162, 313–321.

    PubMed  CAS  Google Scholar 

  34. Hunter, W. D., Martuza, R. L., Feigenbaum, F., et al. (1999) Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73, 6319–6326.

    PubMed  CAS  Google Scholar 

  35. Todo, T., Feigenbaum, F., Rabkin, S. D., et al. (2000) Viral shedding and biodistribution of G207, a multimutated, conditionally-replicating herpes simplex virus type 1, after intracerebral inoculation in Aotus. Mol. Ther. 2, 588–595.

    Article  PubMed  CAS  Google Scholar 

  36. Varghese, S., Newsome, J. T., Rabkin, S. D., et al. (2001) Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 12, 999–1010.

    Article  PubMed  CAS  Google Scholar 

  37. Markert, J. M., Medlock, M. D., Rabkin, S. D., et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867–874.

    Article  PubMed  CAS  Google Scholar 

  38. Papanastassiou, V., Rampling, R., Fraser, M., et al. (2002) The potential for efficacy of the modified (ICP 34.5 (−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9, 398–406.

    Article  PubMed  CAS  Google Scholar 

  39. Todo, T., Rabkin, S. D., Sundaresan, P., et al. (1999) Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10, 2741–2755.

    Article  PubMed  CAS  Google Scholar 

  40. Toda, M., Rabkin, S. D., Kojima, H., and Martuza, R. L. (1999) Herpes simplex virus as an “in situ cancer vaccine” for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10, 385–393.

    Article  PubMed  CAS  Google Scholar 

  41. Nakano, K., Todo, T., Chijiiwa, K., and Tanaka, M. (2001) Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol. Ther. 3, 431–437.

    Article  PubMed  CAS  Google Scholar 

  42. Endo, T., Toda, M., Watanabe, M., et al. (2002) In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther. 9, 142–148.

    Article  PubMed  CAS  Google Scholar 

  43. Todo, T., Rabkin, S. D., Chahlavi, A., and Martuza, R. L. (1999) Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene Ther. 10, 2869–2878.

    Article  PubMed  CAS  Google Scholar 

  44. Langenberg, A. G., Corey, L., Ashley, R. L., Leong, W. P., and Straus, S. E. (1999) A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N. Engl. J. Med. 341, 1432–1438.

    Article  PubMed  CAS  Google Scholar 

  45. Xu, F., Schillinger, J. A., Sternberg, M. R., et al. (2002) Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J. Infect. Dis. 185, 1019–1024.

    Article  PubMed  Google Scholar 

  46. Chahlavi, A., Rabkin, S., Todo, T., Sundaresan, P., and Martuza, R. (1999) Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 6, 1751–1758.

    Article  PubMed  CAS  Google Scholar 

  47. Miller, C. G. and Fraser, N. W. (2000) Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 60, 5714–5722.

    PubMed  CAS  Google Scholar 

  48. Delman, K. A., Bennett, J. J., Zager, J. S., et al. (2000) Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther. 11, 2465–2472.

    Article  PubMed  CAS  Google Scholar 

  49. York, I. A., Roop, C., Andrews, D. W., Riddell, S. R., Graham, F. L., and Johnson, D. C. (1994) A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77, 525–535.

    Article  PubMed  CAS  Google Scholar 

  50. Ahn, K., Meyer, T. H., Uebel, S., et al. (1996) Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 15, 3247–3255.

    PubMed  CAS  Google Scholar 

  51. Mohr, I. and Gluzman, Y. (1996) A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 15, 4759–4766.

    PubMed  CAS  Google Scholar 

  52. Mohr, I., Sternberg, D., Ward, S., Leib, D., Mulvey, M., and Gluzman, Y. (2001) A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. 75, 5189–5196.

    Article  PubMed  CAS  Google Scholar 

  53. Toda, M., Martuza, R. L., Kojima, H., and Rabkin, S. D. (1998) In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457–4464.

    PubMed  CAS  Google Scholar 

  54. Todo, T., Martuza, R. L., Dallman, M. J., and Rabkin, S. D. (2001) In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61, 153–161.

    PubMed  CAS  Google Scholar 

  55. Carew, J. F., Kooby, D. A., Halterman, M. W., Kim, S. H., Federoff, H. J., and Fong, Y. (2001) A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol. Ther. 4, 250–256.

    Article  PubMed  CAS  Google Scholar 

  56. Miyatake, S., Martuza, R. L., and Rabkin, S. D. (1997) Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 4, 222–228.

    PubMed  CAS  Google Scholar 

  57. Zager, J. S., Delman, K. A., Malhotra, S., et al. (2001) Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol. Med. 7, 561–568.

    PubMed  CAS  Google Scholar 

  58. Toda, M., Martuza, R. L., and Rabkin, S. D. (2000) Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol. Ther. 2, 324–329.

    Article  PubMed  CAS  Google Scholar 

  59. Ali, S. A., Lynam, J., McLean, C. S., et al. (2002) Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. J. Immunol. 168, 3512–3519.

    PubMed  CAS  Google Scholar 

  60. Dranoff, G., Jaffee, E., Lazenby, A., et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocye-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539–3543.

    Article  PubMed  CAS  Google Scholar 

  61. Andreansky, S., He, B., van Cott, J., et al. (1998) Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5, 121–130.

    Article  PubMed  CAS  Google Scholar 

  62. Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., and Markert, J. M. (2000) Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA 97, 2208–2213.

    Article  PubMed  CAS  Google Scholar 

  63. Wong, R. J., Patel, S. G., Kim, S., et al. (2001) Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther. 12, 253–265.

    Article  PubMed  CAS  Google Scholar 

  64. Bennett, J. J., Malhotra, S., Wong, R. J., et al. (2001) Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann. Surg. 233, 819–826.

    Article  PubMed  CAS  Google Scholar 

  65. Liu, R., Varghese, S., Martuza, R. L., and Rabkin, S. D. (2002) Oncolytic herpes simplex virus (HSV) therapy of breast and prostate cancer in C3(1)/SV40-TAg transgenic mice. Mol. Ther. 5, S302.

    Article  Google Scholar 

  66. Fong, Y., Kemeny, N., Jarnagin, W., et al. (2002) Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Proc. Am. Soc. Clin. Oncol. 21, 8a.

    Google Scholar 

  67. Chase, M., Chung, R. Y., and Chiocca, E. A. (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16, 444–448.

    Article  PubMed  CAS  Google Scholar 

  68. Nakamura, H., Mullen, J. T., Chandrasekhar, S., Pawlik, T. M., Yoon, S. S., and Tanabe, K. K. (2001) Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 61, 5447–5452.

    PubMed  CAS  Google Scholar 

  69. Chahlavi, A., Todo, T., Martuza, R. L., and Rabkin, S. D. (1999) Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1, 162–169.

    Article  PubMed  CAS  Google Scholar 

  70. Toyoizumi, T., Mick, R., Abbas, A. E., Kang, E. H., Kaiser, L. R., and Molnar-Kimber, K. L. (1999) Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 10, 3013–3029.

    Article  PubMed  CAS  Google Scholar 

  71. Advani, S. J., Sibley, G. S., Song, P. Y., et al. (1998) Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 5, 160–165.

    Article  PubMed  CAS  Google Scholar 

  72. Bradley, J. D., Kataoka, Y., Advani, S., et al. (1999) Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res. 5, 1517–1522.

    PubMed  CAS  Google Scholar 

  73. Chung, S. M., Advani, S. J., Bradley, J. D., et al. (2002) The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 9, 75–80.

    Article  PubMed  CAS  Google Scholar 

  74. Jorgensen, T. J., Katz, S., Wittmack, E. K., et al. (2001) Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 3, 451–456.

    Article  PubMed  CAS  Google Scholar 

  75. Blank, S. V., Rubin, S. C., Coukos, G., Amin, K. M., Albelda, S. M., and Molnar-Kimber, K. L. (2002) Replicationselective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum. Gene Ther. 13, 627–639.

    Article  PubMed  CAS  Google Scholar 

  76. Muldoon, L. L., Nilaver, G., Kroll, R. A., et al. (1995) Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am. J. Pathol. 147, 1840–1851.

    PubMed  CAS  Google Scholar 

  77. Rainov, N. G., Zimmer, C., Chase, M., et al. (1995) Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum. Gene Ther. 6, 1543–1552.

    Article  PubMed  CAS  Google Scholar 

  78. Barnett, F. H., Rainov, N. G., Ikeda, K., et al. (1999) Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. 6, 14–20.

    Google Scholar 

  79. Ikeda, K., Ichikawa, T., Wakimoto, H., et al. (1999) Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881–887.

    Article  PubMed  CAS  Google Scholar 

  80. Todo, T. (2002) Oncolytic virus therapy using genetically engineered herpes simplex viruses. Hum. Cell 15, 151–159.

    Article  PubMed  Google Scholar 

  81. Spaete, R. R. and Frenkel, N. (1982) The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning-amplifying vector. Cell 30, 295–304.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan

    Tomoki Todo

  2. Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA

    Samuel D. Rabkin

Authors
  1. Tomoki Todo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel D. Rabkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  2. Division of Human Gene Therapy, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  3. Division of Human Gene Therapy, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  4. Division of Human Gene Therapy, Department of Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Todo, T., Rabkin, S.D. (2005). Development of Oncolytic Replication-Competent Herpes Simplex Virus Vectors. In: Curiel, D.T., Douglas, J.T. (eds) Cancer Gene Therapy. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59259-785-7_13

Download citation

Publish with us

Policies and ethics

Search

Navigation